title: Effect of nandrolone decanoate and 1-alpha-hydroxy-calciferol on patients with vertebral osteoporotic collapse. A double-blind clinical trial.
abstract: Eighty-eight postmenopausal women with at least one vertebral collapse were randomly assigned to two groups of 44 patients each. All patients were treated for a period of 12 months with 50 mg of nandrolone decanoate every 3 weeks or 1 microgram of 1-alpha-hydroxy-calciferol daily. Both groups received an identical placebo of the inactive drug. Pain intensity was significantly decreased in the nandrolone group and mobility was improved. Patients treated with vitamin D metabolite had also a beneficial but less obvious clinical result. Bone mineral measurements showed an increase of 5% in the nandrolone decanoate group, but a 2.5% decrease in the vitamin D metabolite group. Biochemical results showed a significant hypercalciuric effect of vitamin D metabolite, while nandrolone decanoate caused a reduction in calcium/creatinine excretion. No difference in serum lipids was found during the annual treatment in both groups. It is concluded that nandrolone decanoate has a beneficial effect in clinical symptoms, bone mineral density and biochemical parameters in patients with established osteoporotic vertebral fractures.
authors.affiliation: Laboratory for the Research of Musculoskeletal System Th Garofalidis, University of Athens, Faculty of Medicine, KAT Hospital, Kifissia, Greece.
authors.forename: G P
authors.initials: GP
authors.lastname: Lyritis
authors.forename: C
authors.initials: C
authors.lastname: Androulakis
authors.forename: B
authors.initials: B
authors.lastname: Magiasis
authors.forename: Z
authors.initials: Z
authors.lastname: Charalambaki
authors.forename: N
authors.initials: N
authors.lastname: Tsakalakos
mesh_terms: D000368:Aged; D015519:Bone Density; D002118:Calcium / Q000652:urine; D003404:Creatinine / Q000652:urine; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy; D016103:Spinal Fractures / Q000188:drug therapy* / Q000209:etiology
chemical_list: D006887:Hydroxycholecalciferols; D009277:Nandrolone; D003404:Creatinine; D000077603:Nandrolone Decanoate; D002118:Calcium; C008088:alfacalcidol